Skip to main content
. Author manuscript; available in PMC: 2022 Aug 4.
Published in final edited form as: Int J Cancer. 2022 Jul 19;151(11):1913–1924. doi: 10.1002/ijc.34202

Table 4.

Data for anti-COVID-19 IgG antibodies

Subject ID Diagnosis Therapy Antibody ratio* Phase of therapy at COVID-19 diagnosis Antibody testing timepoint (Days)# Comment
2 ALL HSCT 6.7 305 days post-HSCT 38
3 ALL CAR Negative 110 B-cell aplasia
4 ALL HSCT 7.5 165 days post-HSCT 17
5 ALL CAR 6.9 27 On IVIG, received monoclonal, B-cell aplasia
7 ALL HSCT 4.9 923 days post-HSCT 41
8 ALL CAR 7.7 28 On IVIG, was negative at 16 days, B-cell aplasia
9 ALL HSCT 4.8 258 days post-HSCT 50
10 ALL HSCT 6.9 1075 days post-HSCT 26
12 Neuroblastoma HSCT 1.5 17
13 ALL CAR Negative 52 B-cell aplasia
16 NHL CAR Negative 39 B-cell aplasia
18 Soft tissue sarcoma HSCT Negative 14
20 ALL Chemo 2.3 Delayed Intensification 83
22 ALL Chemo Negative maintenance 27
23 Bone sarcoma Chemo 7.5 Induction week 1 4
25 Neuroblastoma Chemo Negative Induction cycle 2 31
37 AML Chemo 1.4 At cancer diagnosis 39 Was negative at 21 days
40 ALL Chemo Negative Consolidation 86
42 ALL Chemo Negative Induction day 27 3
52 Sarcoma Chemo Negative Cycle 5 19
53 AML Chemo 2 At cancer diagnosis 2 Received convalescent plasma
58 ALL Chemo 11.2 Induction day 5 46 Antibody ratio = 8.2 at day 117
59 ALL Chemo Negative Maintenance 31
60 NHL Chemo Negative COP-R prophase (week 1 of induction chemotherapy) 149
64 Relapsed ALL Chemo 9.3 Re-induction
Day 10		 38
75 ALL Chemo Negative Delayed intensification 31
78 ALL Chemo 4.4 Maintenance 23
79 Neuroblastoma HSCT Negative 161 days post-HSCT, cycle 3 of post-HSCT anti-GD2 immunotherapy 7
84 ALL CAR Negative 2142 days post-CAR 148 B-cell aplasia
85 ALL Chemo 2.9 Induction day 27 2 Antibody titer 1.2 at day 92
86 ALL Chemo 2.2 Maintenance 19
87 ALL Chemo 8.3 Interim maintenance 2 received monoclonal, antibody titer 8.3 at day 98
*

Antibody ratio: ratio of sample to internal control17. Negative: Antibody ratio <1.2. Days post-infection: day 0 = day of PCR diagnosis of COVID-19.

#

Time interval between the date of the first positive COVID-19 RT-PCR and the date when the sample was obtained for antibody testing. COP-R: cyclophosphamide, vincristine, prednisone, and Rituxumab.